Aptevo Therapeutics (APVO) Operating Income (2016 - 2022)
Historic Operating Income for Aptevo Therapeutics (APVO) over the last 8 years, with Q4 2022 value amounting to -$7.7 million.
- Aptevo Therapeutics' Operating Income fell 9019.8% to -$7.7 million in Q4 2022 from the same period last year, while for Dec 2022 it was -$28.6 million, marking a year-over-year decrease of 3383.64%. This contributed to the annual value of -$28.6 million for FY2022, which is 3383.64% down from last year.
- Latest data reveals that Aptevo Therapeutics reported Operating Income of -$7.7 million as of Q4 2022, which was down 9019.8% from -$7.8 million recorded in Q3 2022.
- Over the past 5 years, Aptevo Therapeutics' Operating Income peaked at -$4.0 million during Q4 2021, and registered a low of -$13.5 million during Q1 2018.
- In the last 5 years, Aptevo Therapeutics' Operating Income had a median value of -$7.6 million in 2022 and averaged -$8.5 million.
- In the last 5 years, Aptevo Therapeutics' Operating Income soared by 4721.62% in 2020 and then crashed by 9019.8% in 2022.
- Over the past 5 years, Aptevo Therapeutics' Operating Income (Quarter) stood at -$12.1 million in 2018, then increased by 21.09% to -$9.6 million in 2019, then increased by 28.75% to -$6.8 million in 2020, then skyrocketed by 40.75% to -$4.0 million in 2021, then crashed by 90.2% to -$7.7 million in 2022.
- Its Operating Income stands at -$7.7 million for Q4 2022, versus -$7.8 million for Q3 2022 and -$7.6 million for Q2 2022.